Pharmaceutical manufacturing has run on batch production for over a century: react, isolate, dry, test, release, repeat.
It works. But it is slow, wasteful, variable, and increasingly misaligned with where global regulators are pushing quality standards.
In 2022, ICH published Q13,[1] the first global guideline for continuous manufacturing API pharmaceutical production.
This blog explains what continuous manufacturing APIs future production means for manufacturers and buyers, and how to evaluate the transition.
ICH Q13 was officially accepted in November 2022. It was the first universal guideline around the world for continuous manufacturing concerning the regulatory approval for the production of pharmaceuticals.
It was also the first guideline established by the USFDA, EMA, PMDA, and Health Canada.
By 2024, the US FDA had approved more than 15 continuous[2] manufacturing products.
The first approved continuous manufacturing facility for a small molecule was Vertex Pharmaceuticals (Orkambi) in 2015.
Batch Manufacturing’s Efficiency Ceiling: Why the Industry Needs a New Production Paradigm
Batch manufacturing has served pharma well, but its structural limitations now create measurable quality, efficiency, and competitive problems that incremental improvement cannot resolve.
What Batch Manufacturing Is and What It Cannot Do
In batch manufacturing, each API step- reaction, extraction, crystallisation, and drying completes in a discrete vessel before the next begins.
The entire quantity is processed as one unit, tested, and released as a single batch, making every batch a separate quality event, regulatory record, and deviation opportunity.
Inter-batch variability in CQAs assay, impurity profile, particle size, and polymorphic form is a documented feature of batch production, with ±5-15% inter-batch variability for particle size and ±2-5% for assay values recorded across API categories.
ICH Q8 and Q10[3] manage this through QbD and pharmaceutical quality systems.
Continuous manufacturing addresses variability at the process level, not just the quality system level.
The Four Structural Limitations of Batch API Manufacturing
Four structural problems are driving the industry toward continuous manufacturing API pharmaceutical production:
In a typical year, API manufacturing is done in 200 batches. From this, it can be expected that 10-20 batches will fail, as, on average, 5-10% of API batches do not meet acceptance criteria.
This results in the destruction of the API. However, the use of Continuous Manufacturing and the Real-Time PAT (Process Analytical Technologies) detection and correction reduces the likelihood of rejection.
| Micro-summary: Batch API manufacturing carries a 5-10% batch failure rate, ±2-15% CQA variability at scale, and a compliance documentation burden that grows linearly with production volume. These are structural limitations of the batch model not isolated quality events. ICH Q13 and continuous manufacturing address them at the process level. |
The Cost of Staying Batch: Efficiency Losses, Regulatory Pressure, and Global Competitiveness Risk
Because of constraints with regulatory compliance and a decline in competitiveness, batch manufacturing is becoming less efficient and more expensive, as there is a developing preference for continuous manufacturing.
The Quantified Efficiency Gap: What Batch Manufacturing Wastes
Cycle time, footprint, and solvent metrics illustrate the gap identified between Continuous Manufacturing (CM) and Batch Manufacturing (BM) API production.
CM is expected to reduce production footprint by 60%, reduce solvent consumption by 50%, and reduce cycle time from days to hours, thereby improving COGS and global tender pricing.
| Metric | Batch Process | Continuous Manufacturing (CM) |
| Manufacturing Cycle Time | Days to weeks | Processing takes 30-80% less time[4] |
| Physical Plant Footprint | Facilities are large and contain multiple vessels | Facilities are 40-60% smaller |
| Solvent & Reagent Consumption | Used in high volumes | Consumption is 25-50% lower[5] |
| Energy Consumption | Difficult to scale due to high energy demand per batch | Energy usage is 20-40% lower |
| Water Usage | Large volumes required for cleaning and washing | Water requirement is significantly lower |
Regulatory Pressure: USFDA and EMA Are Actively Incentivising CM Adoption
The US FDA’s Emerging Technology Program (ETP) started in 2014 and offered CM adopters pre-review meetings and prioritized reviews. Since 2023, more than 50% of ETP processes comprised continuous manufacturing in the Office of Pharmaceutical Quality (USFDA).
The momentum in Europe is seen with the European Medicines Agency’s (EMA) continuous manufacturing reflection paper on APIs and the adoption of ICH Q13. Manufacturers who postpone embracing CM will have increasing regulatory gaps.
Competitive Erosion: The Global CM Investment Race
European and US CMOs are building CM capacity as a differentiated service.
For Indian API manufacturers, CM-equipped rivals delivering superior CQA performance and lower COGS simultaneously pose a structural competitive threat.
Global Continuous Manufacturing Market: Current Continuous Manufacturing in Pharmaceuticals is valued at USD 2.08 billion in 2023 and is expected to reach USD 4.67 billion by 2031[6] based on a CAGR of 10.6%.
| Micro-Summary: CM delivers 30-80% cycle time reduction and 40-60% footprint savings. USFDA ETP is now majority CM-focused at 50%+ of interactions. The global CM market grows at 10.6% CAGR toward USD 4.67B by 2031. Now let us examine what continuous manufacturing is and how it works. |
What Continuous Manufacturing Is and How It Works for API Production
Continuous manufacturing feeds raw materials into an integrated process train that reacts, purifies, and outputs finished API without stopping, eliminating discrete batch cycles.
The Two Modes of Continuous API Manufacturing
| CM Mode | How It Works | Best Suited For | Capital Investment | Regulatory Filing |
| Continuous Flow Chemistry (End-to-End CM) | All manufacturing steps run in a connected, uninterrupted flow through reactors, separators, and crystallizers. | Complex multi-step APIs, exothermic or hazardous reactions, and small molecules with 3-8 synthesis steps. | USD 10-50 million+ | Full ICH Q13 dossier required; design space documentation is mandatory. |
| Integrated Continuous Processing (Hybrid CM) | Selected unit operations are converted to continuous mode, while intermediate hold steps may still be present. | APIs where one or two batch operations are the main production bottlenecks. | USD 2-15 million | ICH Q13 applies to the converted continuous steps; existing batch sections retain their current validation requirements. |
Key Enabling Technologies for Continuous API Manufacturing
Three enablers distinguish continuous manufacturing API pharmaceutical production:
How Quality Is Assured in Continuous Manufacturing Real-Time Release Testing (RTRT)
Batch release testing averages 5-14 days. In continuous manufacturing, quality is monitored continuously via PAT against the validated design space.
This is Real-Time Release Testing (RTRT), defined in ICH Q8(R2) as “the ability to evaluate and ensure the quality of in-process and/or final product based on process data.
Real-time release testing in continuous manufacturing API compresses release to under 24 hours and enables immediate diversion of non-conforming material.
ICH Q13 Section 5.3 confirms RTRT can replace conventional end-product testing when the PAT system is appropriately validated.
| Micro-Summary: CM operates via end-to-end flow chemistry (USD 10-50M) or hybrid processing (USD 2-15M), enabled by PAT, flow reactors, and APC. RTRT compresses release from 5-14 days to under 24 hours. Now let us examine the global regulatory framework governing CM submissions. |
Regulatory Framework for Continuous Manufacturing of APIs: ICH Q13, USFDA, and EMA
Understanding agency-specific CM filing requirements is essential before investment.
USFDA ICH Q13 continuous manufacturing guidance API compliance is the global standard, but material agency differences still remain.
ICH Q13 (2022): The Global Continuous Manufacturing Regulatory Standard
ICH Q13, adopted November 2022, is the first globally harmonised guideline for continuous manufacturing of drug substances and drug products.
Implemented by USFDA, EMA, PMDA, and Health Canada, it covers CM dossier preparation, control strategy, batch definition, process characterisation, and validation, superseding prior agency-specific CM guidance.
| ICH Q13 Element | What It Requires | Implication for API Manufacturers |
| Batch Definition | Defined by mass, volume, or operating time not vessel fill. Must be justified in the dossier. | New concept for teams accustomed to vessel-based batch definition |
| Control Strategy | Validated PAT monitoring, process parameter and material attribute controls, and OOS diversion criteria. | PAT sensor validation and automated diversion documentation required |
| Design Space | Multidimensional process parameter and material attribute range within which quality is assured. | Full QbD process characterisation at CM scale required |
| Process Validation | Continued process verification (CPV) via ongoing PAT statistical monitoring replaces traditional prospective batches. | Simpler batch count but robust statistical monitoring required from first commercial batch |
USFDA vs. EMA: Key Differences in CM Assessment Approach
| Micro-Summary: ICH Q13 (November 2022) did standardization for USFDA, EMA, and PMDA. The USFDA is at the forefront, with 15+ approvals. The EMA and PMDA aligned with Q13 in 2023. Exporters from India file according to the requirements of the destination market. We will now determine the API categories that are best positioned for CM. |
Which APIs Are Best Suited for Continuous Manufacturing? Category Suitability Analysis
Not all APIs are equally suited to continuous manufacturing.
Suitability depends on chemistry, volume, hazard profile, and demand stability directly relevant to buyers evaluating which APIs are suitable for continuous manufacturing.
API Category Suitability Scorecard for Continuous Manufacturing
| API Category | Key APIs | CM Suitability | Primary CM Advantage | Key Challenge | Adoption Status 2026 |
| High-Volume Small Molecule APIs | Paracetamol, Ibuprofen, Metformin, Aspirin | Very High | Throughput gains; COGS reduction; minimal chemistry complexity | Low margin may limit ROI unless at very large scale | Early commercial adoption – Indian CMOs and MNCs |
| Exothermic / Hazardous Reaction APIs | Nitration, cryogenic synthesis, exothermic oxidations | Very High | Microreactor safety – eliminates large-scale hazardous intermediate accumulation | Specialised flow reactor engineering; complex safety validation | Active European and US CM specialists; Indian interest growing |
| Antimalarial APIs (ACT) | Artesunate, Artemether diazomethane/photochemical steps | High | Photochemical/hazardous steps favour flow chemistry API manufacturing benefits 2026 | WHO-PQ filing requires additional CM data package | Emergin academic-industrial partnerships; documented large-scale CM projects for artemisinin |
| Cardiovascular / Metabolic APIs | Atorvastatin, Amlodipine, Ramipril, Lisinopril | High | High global demand; strong continuous manufacturing API cost reduction quality improvement potential | Multi-step synthesis with crystallisation – each step requires separate CM optimisation | Moderate primarily MNC API divisions |
| Antibiotic APIs | Amoxicillin, Azithromycin, Ciprofloxacin | Moderate | High volume; supply security; significant solvent reduction | Fermentation-derived materials; semi-synthetic complexity | Limited- batch dominant; selective step conversion emerging |
| Peptide APIs | GLP-1 agonists (Semaglutide intermediates), insulin | Moderate-High | Continuous flow SPPS advancing rapidly; dramatic scale advantages | Specialised flow SPPS equipment; preparative HPLC integration complex | Active R&D among innovator companies and CDMOs; commercial adoption expected 2026-2028Â |
| Highly Potent APIs (HPAPIs) | Oncology APIs, ADC payloads, cytotoxic agents | High | CM dramatically reduces operator HPAPI exposure versus batch | Specialised containment engineering; high regulatory scrutiny | Growing – HPAPI CM is a CMO differentiation strategy in US and Europe |
Peptide API Momentum: GLP-1 receptor agonist API demand grows at over 30% year-on-year through 2026. Continuous flow solid-phase peptide synthesis (CF-SPPS) reduces cycle time by 60-80% versus batch SPPS.
| Micro-Summary: High-volume small molecules, exothermic APIs, and HPAPIs offer the strongest CM case in 2026. Peptide APIs are a fast-emerging 60-80% cycle time reduction against 30%+ GLP-1 demand growth. Now let us examine the practical readiness framework for CM transition. |
CM Transition Readiness: A Practical Framework for API Manufacturers
A CM transition requires structured evaluation across five dimensions, applicable to both manufacturers assessing investment and buyers evaluating CM-capable API suppliers.
| Readiness Dimension | Assessment Question | Indicator of CM Readiness | Indicator of CM Barrier |
| Chemistry Suitability | Is the synthesis route compatible with continuous flow? | Exothermic reactions, hazardous intermediates, photochemical steps, telescoped multi-step sequences | Fermentation-derived APIs, highly insoluble intermediates, complex multi-phase reactions with no flow chemistry precedent |
| Production Volume | Is volume sufficient to justify investment? | APIs at >1 MT/year – CM ROI improves meaningfully at scale | APIs at <100 kg/year – batch more capital-efficient; CM payback impractically long |
| Regulatory Filing Strategy | Is the target agency CM-ready? | USFDA (via ETP), EMA, PMDA ICH Q13-defined pathways exist | Markets without CM guidance – additional dossier justification or parallel batch filing required |
| PAT and Digital Infrastructure | Does the manufacturer have CM-supporting systems? | In-line NIR/Raman, validated PAT, MES/ERP integration, statistical process control | At-line or off-line testing only; no in-line sensors; no model predictive control capability |
| Capital and ROI Model | Does the business case support CM investment? | High-demand APIs, HPAPI containment, exothermic safety – CM payback <5 years plausible | Low-volume APIs, stable batch processes with no quality problems – batch remains rational |
These five dimensions provide a structured decision tool for manufacturers evaluating continuous manufacturing vs batch manufacturing API investment and for procurement teams assessing supplier CM capabilities.
| What’s Next?: Now let us address the most frequently asked questions on continuous manufacturing API pharmaceutical production. |
FAQ – Continuous Manufacturing of APIs
Q: What is the difference between continuous manufacturing and batch manufacturing for APIs?
A: In batch manufacturing, products are manufactured and released independently. It follows the 5-14 days cycle on average. Continuous manufacturing feeds raw materials into an integrated process train monitored in real time via PAT (Process Analytical Technology), enabling real-time release testing and continuous manufacturing API and compressing release to under 24 hours.
Documented advantages: 30-80% cycle time reduction, 40-60% smaller footprint, and 25-50% lower solvent consumption versus batch.
Q: What is ICH Q13 and why does it matter for API continuous manufacturing?
A: ICH Q13: Continuous Manufacturing of Drug Substances and Drug Products is the first globally harmonised regulatory guideline for continuous manufacturing, adopted in November 2022. USFDA ICH Q13 continuous manufacturing guidance API compliance is now required for CM submissions to USFDA, EMA, PMDA, and Health Canada.
ICH Q13 covers batch definition methodology, PAT-based control strategy, design space characterisation, and continued process verification (CPV) as the accepted validation approach. ICH Q13 compliance is non-negotiable for any CM-produced drug substance targeting these markets.
Q: Which types of APIs benefit most from continuous manufacturing?
A: The highest-suitability categories in 2026 are: (1) High-volume small molecule APIs Paracetamol, Ibuprofen, Metformin; (2) Exothermic/hazardous reaction APIs where microreactor safety is decisive; (3) HPAPIs where CM containment reduces operator exposure; and (4) Peptide APIs CF-SPPS cuts cycle time 60-80% against 30%+ GLP-1 demand growth.
Full assessment of which APIs are suitable for continuous manufacturing requires chemistry-specific and volume-specific evaluation against the five-dimension readiness framework.
Q: Does continuous manufacturing reduce API production costs?
A: Yes, continuous manufacturing reduces API production costs. USFDA and ISPE data confirm 30-80% shorter cycle times, 40-60% smaller footprint, 25-50% lower solvent use, and 20-40% lower energy consumption versus batch.
Capital ranges from USD 10-50M for end-to-end CM to USD 2-15M for hybrid conversions. CM payback under five years is documented for high-demand APIs, exothermic reaction APIs, and HPAPIs with high batch containment costs.
Q: Can an Indian API manufacturer supply CM-produced APIs to the US and EU markets?
Indian API manufacturers supply CM-produced APIs to the US and EU markets as long as the CM process meets the importing country requirements. For the US: submit under USFDA ICH Q13 continuous manufacturing guidance for APIs through ETP, where CM constitutes more than 50% of active ETP interactions (2023).
For the EU: follow the EMA’s continuous manufacturing reflection paper for APIs and ICH Q13 (adopted 2023). CDSCO approval is not needed for products meant for export.
The sites need to have been inspected by USFDA or EMA, and the CTD Module 3 needs to be in line with the ICH Q13 control strategy and full validation requirements.
Conclusion: Continuous Manufacturing Is a Present-State Commercial Reality and a Strategic Imperative
Continuous manufacturing is not a future-state aspiration; it is a present-state commercial reality: 15+ USFDA-approved products, a globally harmonised pathway under ICH Q13, and a market growing at 10.6% CAGR toward USD 4.67 billion by 2031.
The efficiency case is documented as 30-80% cycle time reduction, 40-60% smaller footprint, 25-50% lower solvent use, and release compressed from 14 days to under 24 hours. USFDA, EMA, and ICH are aligned.
Companies investing in CM infrastructure across PAT systems, process development, and continuous manufacturing, with regulatory approval and pharmaceutical filing capability, will be the preferred API suppliers of the next decade.
Actiza Pharmaceutical Pvt. Ltd. is focusing on the priority categories of API’s to establish continuous manufacturing.
The benefits include the high level of efficiency, consistency of quality, and regulatory compliance that global pharma buyers require.
- https://www.federalregister.gov/documents/2023/03/01/2023-04212/q13-continuous-manufacturing-of-drug-substances-and-drug-products-international-council-for
- https://www.raps.org/resource/fda-official-17-drugs-approved-using-continuous-manufacturing-growth-seen-in-emerging-tech-program.html
- https://www.ich.org/page/quality-guidelines
- https://clarkstonconsulting.com/insights/continuous-pharmaceutical-manufacturing/
- https://www.continuuspharma.com/media-publications/continuous-manufacturing-drives-down-eenvironmental-factor-via-solvent-recovery-system/
- https://www.theinsightpartners.com/reports/pharmaceutical-continuous-manufacturing-market
